The impact of CPAP therapy on glycemic control in patients with obstructive sleep apnea and type 2 diabetes by DebRoy, Whitney
Abstract
Obstructive sleep apnea (OSA) is a common comorbidity found in 
patients with Type 2 diabetes (T2DM) and has been identified as 
an independent risk factor in developing T2DM. Continuous 
positive airway pressure (CPAP) is the first line treatment for 
OSA. This study reviewed six articles that assessed the impact of 
CPAP treatment on glycemic control in patients with T2DM and 
OSA compared to no treatment. The results showed that CPAP 
does not lead to improved glycemic control in the short term but 
may be associated with a slower rise in hemoglobin A1c (HbA1c) 
in the long term. CPAP treatment led to significant improvements 
in blood pressure and sleep scores, supporting the use of CPAP in 
patients with T2DM and OSA regardless of its effect on HbA1c.
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T2DM is a chronic illness that affects over 30 million (9.4%) 
Americans and is associated with significant morbidity and 
mortality1
• Approximately 70% of patients with T2DM have OSA2
• Sleep fragmentation and intermittent hypoxia in OSA 
contributes to insulin resistance and the development of T2DM3
• OSA severity, measured by apnea-hypopnea index, is positively 
correlated with HbA1c3
• OSA is a risk factor for T2DM, independent of obesity3
• First line treatment for OSA is continuous positive airway 
pressure (CPAP)3
Research question: In adults aged 18 or older with OSA and 
T2DM, does use of CPAP result in improved glycemic control 
compared to no CPAP use?
Methods
Introduction
A literature search was conducted using PubMed, EBSCO and 
Google Scholar in November 2018. Six articles were selected 
based on their study population, intervention, outcome 
measurements, study design and relevance to the research 
question. 
Inclusion criteria: Age ≥ 18; diagnosis of OSA and T2DM; 
HbA1c as primary outcome variable; CPAP as only intervention; 
the study was a clinical trial
Discussion
Table 1. Comparisons of study designs
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The impact of CPAP therapy on glycemic control in patients with obstructive sleep 
apnea and type 2 diabetes
• Guest et al (2014)
ØHbA1c significantly lower in cases than controls at 2, 3, 4, and 5 year follow up. At year 5, 
cases had 0.7% increase in HbA1c compared to a 4.7% increase in controls
• Martinez-Ceron et al (2016)
ØSignificantly lower HbA1c and HOMA-IR in treatment group compared to controls 6 
months. No significant difference at 3 month follow up.
• Lam et al (2014)
Ø Per protocol analysis found a significant reduction in HbA1c in CPAP treated group 
compared to controls
• 2/6 studies found improved glycemic control after 
treatment with CPAP
Ø1 of 4 RCTs showed a significant difference
ØCC showed slower rise in HbA1c over time
• None showed significant difference in FBG
• 3 of 4 studies found that treatment with CPAP 
significantly lowered blood pressure
• Strengths
Ø4/6 studies were RCTs
ØAll studies used HbA1c as primary outcome 
variable
• Limitations
ØCC and RC studies subject to bias
ØShort study durations in RCTs
ØPoor CPAP compliance in majority of studies
ØBaseline OSA severity and HbA1c levels
varied across studies, limiting generalizability
Study Design Population 
Demographics
Study 
Duration
Intervention Control Outcome 
Variables
Guest et al 
(2014)
CC 165 male
135 female
5 years CPAP, 
unspecified
O HbA1c, BP
Lam et al 
(2014)
RCT 52 male
12 female
3 months Fixed CPAP O HbA1c, FBG, BP
Martinez-
Ceron et 
al (2016)
RCT 30 male
20 female
6 months Fixed CPAP O HbA1c, FBG, 
HOMA-IR, 
QUICKI
Prasad et 
al (2012)
RC 221 male 12 months Fixed CPAP or 
APAP
N/A HbA1c, FBG, BP
Shaw et al 
(2016)
RCT 192 male
106 female
6 months Auto-titrating 
CPAP
O HbA1c, FBG, BP
West et al 
(2007)
RCT 42 male 3 months Auto-titrating 
CPAP
P HbA1c, HOMA-
IR, FBG
Note: APAP= automatic positive airway pressure, BP= blood pressure, CC= case control study, CPAP= continuous 
positive airway pressure, FBG=fasting blood glucose, HbA1c= hemoglobin A1c, HOMA-IR= Homeostasis Model 
Assessment-Insulin Resistance, P= placebo, QUICKI = qualitative insulin sensitivity check index, RC= retrospective 
cohort study, RCT= randomized control trial
Study HbA1c FBG HOMA-IR BP CPAP use 
(hrs/night)
Guest et al (2014) S N/A N/A S A*
Lam et al (2014) NS NS N/A S I
Martinez-Ceron et al (2016) S NS S N/A A
Prasad et al (2012) NS NS N/A S A*
Shaw et al (2016) NS NS N/A NS A
West et al (2007) NS NS NS N/A I
Note: A= adequate (≥4), I= inadequate (<4)N= not significant, N/A= not applicable, S= significant (p<.05), *= significant 
missing data
Table 2. Comparisons of study results
Results
• Overall, the evidence shows that OSA treatment 
with CPAP does not improve glycemic control in 
patients with comorbid OSA and T2DM. 
• Guest et al suggested that CPAP treatment may 
lead to more stable HbA1c long term 
• CPAP treatment improves blood pressure 
Recommendations for clinical practice
• Screen patients with T2DM for symptomatic OSA
• Treat patients with OSA and T2DM with CPAP 
given its effect on blood pressure and sleep scores
Future research: 
• Effect of CPAP treatment in patients with OSA and 
prediabetes
• Qualitative studies assessing barriers to CPAP 
compliance
Conclusion
